|1.||Ueda, Takanori: 2 articles (09/2011 - 02/2007)|
|2.||Yamauchi, Takahiro: 2 articles (09/2011 - 02/2007)|
|3.||Nishi, Rie: 1 article (09/2011)|
|4.||Iwasaki, Hiromichi: 1 article (02/2007)|
|5.||Urasaki, Yoshimasa: 1 article (02/2007)|
|6.||Yamamoto, Shuji: 1 article (02/2007)|
|7.||Kawai, Yasukazu: 1 article (02/2007)|
|8.||Kishi, Shinji: 1 article (02/2007)|
|9.||Takemura, Haruyuki: 1 article (02/2007)|
|10.||Yoshida, Akira: 1 article (02/2007)|
09/01/2011 - "Production of Cl-F-ara-ATP was successfully measured in cultured leukemia HL-60 cells treated in vitro with Cl-F-ara-A. "
01/01/1992 - "Clinical trials of relapsed leukemia in which fludarabine (F-ara-A 5'-monophosphate) and ara-C were given in sequence provided the opportunity to evaluate the effects of ara-C infusion on two sequelae: the pharmacokinetics of F-ara-A in plasma and that of F-ara-ATP in leukemia cells. "
09/01/2011 - "An active metabolite of the anti-leukemia agent clofarabine (Cl-F-ara-A) is an intracellular triphosphate form, Cl-F-ara-ATP. "
02/01/2007 - "Therapy-resistant leukemia may exhibit ara-C resistance, the mechanisms of which might induce cross-resistance to fludarabine with reduced F-ara-ATP formation. "
08/18/2000 - "To test this assay in a more complex biological matrix, perchloric acid extracts of circulating human leukemia cells spiked with known concentrations of ara-GTP and F-ara-ATP were examined. "
|2.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/01/1995 - "To test whether G-CSF infusion prior to ara-C infusion would biologically modulate the accumulation of ara-9-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) and other ara nucleotides in the leukemia blasts during therapy, protocols were designed to infuse G-CSF prior to fludarabine (9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate) and ara-C to increase the accumulation of the active triphosphates [9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate (F-ara-ATP) and ara-CTP] in acute myelogenous leukemia (AML) blasts during therapy. "
01/01/1994 - "The enzymes required in DNA synthesis and affected by F-ara-ATP are ribonucleotide reductase, DNA primase, DNA polymerases, 3'-5' exonuclease activity of DNA polymerases delta and epsilon, and DNA ligase I. The action of fludarabine on DNA replication provides a compelling rationale to use this agent for leukemias where target cells are actively synthesizing DNA, for example acute myelogenous leukemia. "
|4.||Hematologic Neoplasms (Hematological Malignancy)
01/01/1986 - "The pharmacokinetics of 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) in plasma and its biologically active 5'-triphosphate (F-ara-ATP) in leukemic cells obtained from the peripheral blood and bone marrow was evaluated in patients with hematologic malignancies subsequent to the first dose of 20-125 mg/m2 per day for 5 days of F-ara-A 5'-monophosphate (F-ara-AMP) administered as an IV bolus over 30 min. The terminal half-lives of elimination of both F-ara-A (8 h) in plasma and intracellular F-ara-ATP (15 h) were not dependent upon the dose of F-ara-AMP. "
|3.||triphosphoric acid (triphosphate)
|4.||DNA Primase (Primase)
|5.||Granulocyte Colony-Stimulating Factor (G-CSF)
|6.||Ribonucleotide Reductases (Ribonucleotide Reductase)
|7.||Perchloric Acid (Perchlorates)
|9.||Exonucleases (3' 5' Exonuclease)